Castleman’s disease in the HIV-endemic setting

dc.contributor.authorMahroug, Esam-Rajaben_ZA
dc.contributor.authorSher-Locketz, Candiceen_ZA
dc.contributor.authorDesmirean, Minodora-Silviaen_ZA
dc.contributor.authorAbayomi, Emmanuel-Akinolaen_ZA
dc.contributor.authorTomuleasa, Ciprianen_ZA
dc.contributor.authorGrewal, Ravniten_ZA
dc.identifier.citationMahroug, E. R., et al. 2018. Castleman’s disease in the HIV-endemic setting. Cancer Management and Research, 10:4553-4563, doi:10.2147/CMAR.S175648
dc.identifier.issn1179-1322 (online)
dc.descriptionCITATION: Mahroug, E. R., et al. 2018. Castleman’s disease in the HIV-endemic setting. Cancer Management and Research, 10:4553-4563, doi:10.2147/CMAR.S175648.
dc.descriptionThe original publication is available at
dc.description.abstractIntroduction: Castleman’s disease (CD), first described by Benjamin Castleman in 1954, is a giant or angiofollicular lymph node hyperplasia, described as a rare monotypic polyclonal B-cell lymphoproliferative disorder with an incompletely understood pathogenesis and variable clinical behavior. This study aimed to determine the incidence of CD diagnosis over an 11-year period. Additionally, the study aimed to describe the demographic, laboratory, and pathological features of CD. Methods: This is a retrospective study where the demographic and laboratory data were retrieved from the Tygerberg Academic Hospital (TAH) patient electronic records and Tygerberg Lymphoma Study Group (TLSG) and statistical analysis performed on the patients diagnosed with CD. Results: Fifty-four patients were diagnosed with CD during this period. The median age at presentation was 39 years (range: 9–58). HIV serology was available in 53 patients, of which 51 were HIV-positive and two were HIV-negative. The history of initiation of antiretroviral therapy at diagnosis was available in 43 patients (38 on treatment, four were not on treatment, and one defaulted treatment). The median CD4 count was 232.50 cells/μL (range: 2–883). The HIV viral load was performed in 43 patients at diagnosis, which was <49 HIV-1 RNA copies/μL in more than half of the patients (58%). Diagnosis was made on lymph node biopsies in 53 patients, with one case diagnosed on a spleen biopsy. Kaposi sarcoma was found on the same tissue biopsy in 13 cases. A bone marrow biopsy was performed in 31 patients. The predominant features noted were a disorganized hypercellular marrow with plasmocytosis. Conclusion: CD is a rare polyclonal B-cell lymphoproliferative disorder. However, we demonstrated a significant increase in the incidence of HIV-associated multicentric CD over the last decade in our area in South Africa.en_ZA
dc.format.extent11 pagesen_ZA
dc.publisherDove Medical Pressen_ZA
dc.subjectCastleman’s disease (CD)en_ZA
dc.subjectCD4 antigenen_ZA
dc.titleCastleman’s disease in the HIV-endemic settingen_ZA
dc.description.versionPublisher's version
dc.rights.holderAuthors retain copyrighten_ZA

Files in this item


This item appears in the following Collection(s)